Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OPPENHEIMER HOLDINGS INCOPY · Entity 4793 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OPPENHEIMER HOLDINGS INC
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A non-voting common stockSEC Table I · non-derivative | Direct | 5,900 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Other · Acquired 1,400 · Balance 5,900 F1: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2024 Incentive Plan |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2024 Incentive Plan
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Therapeutics, Inc.
Report date February 03, 2026 · Filed February 04, 2026
Section 16 reporting ended · disclosed 2026-02-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-03 · Disposition to issuer · Disposed 22,500 · Balance 42,500 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Row 2 · 2026-02-03 · Other · Disposed 42,500 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F3: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Disposition to issuer · Disposed 20,460 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-03 · Disposition to issuer · Disposed 10,230 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F3: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 16:09 UTC | OPPENHEIMER HOLDINGS INC OPY · Entity 4793 | OtherClass A non-voting common stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012628 · wk-form4_1772208581.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 F1 · date: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2024 Incentive Plan F1 · price: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2024 Incentive Plan Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · derivative · entry 7 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · derivative · entry 6 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · derivative · entry 5 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,230 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · derivative · entry 4 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,230 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,460 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · derivative · entry 3 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,460 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | OtherCommon Stock | 42,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · nonDerivative · entry 2 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F3 · kind: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F3 · price: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 11:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036963 · ownership.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 15:13 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | SaleCommon Stock | 43,000 | $0.11 | $4,816.00 |
DisclosureSEC source: 0001193125-25-324476 · ownership.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.1111 to $0.1130. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 06:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000950170-25-084619 · ownership.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest in 36 equal monthly installments from the grant date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 17:48 UTC | OPPENHEIMER HOLDINGS INC OPY · Entity 4793 | OtherClass A non-voting common stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001775404-25-000002 · wk-form4_1738345697.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2014 Incentive Plan F1 · price: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2014 Incentive Plan Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 16:17 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070668 · ownership.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 19:33 UTC | OPPENHEIMER HOLDINGS INC OPY · Entity 4793 | GrantClass A non-voting common stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001775404-24-000002 · wk-form4_1706556814.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2014 Incentive Plan F1 · price: Represents a restricted stock award granted under the Oppenheimer Holdings Inc. 2014 Incentive Plan Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 19:03 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | PurchaseCommon Stock | 30,000 | $2.18 | $65,367.00 |
DisclosureSEC source: 0001209191-23-057553 · doc4.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 F1 · price: Weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1489 to $2.180 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:02 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035597 · doc4.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on each of September 6, 2023, December 6, 2023, March 6, 2024 and the date which is the earlier of June 6, 2024 and the 2024 annual stockholder meeting, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,460 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 8 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock · 20,460 shares Expires 2029-05-12 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,460 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 7 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,460 shares Expires 2029-05-12 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,230 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 6 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,230 | Not disclosed Strike: $44.02 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 5 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 4 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $19.70 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 3 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 2 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:36 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.22 | Not disclosed |
DisclosureSEC source: 0001209191-22-044461 · doc4.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:20 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-22-034929 · doc4.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · derivative.exercise_date: Consists of Options granted to directors under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 19:18 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $19.70 | $0.00 |
DisclosureSEC source: 0001209191-21-038426 · doc4.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 3, 2021 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 07:51 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | PurchaseCommon Stock | 6,500 | $22.86 | $148,590.00 |
DisclosureSEC source: 0001209191-21-013624 · doc4.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 18:25 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 10,230 | $0.00 Strike: $44.02 | $0.00 |
DisclosureSEC source: 0001209191-20-034791 · doc4.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 4, 2020 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:31 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | PurchaseCommon Stock | 6,500 | $45.50 | $295,750.00 |
DisclosureSEC source: 0001209191-20-005367 · doc4.xml · nonDerivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| May 13, 2019 Filed May 15, 2019 17:08 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (right to buy) · Derivative | 20,460 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030074 · doc4.xml · derivative · entry 1 Kanter Stacy J. · CIK 0001775404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock · 20,460 shares Expires 2029-05-12 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the Option shall vest each month commencing on June 13, 2019, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.